Pharmaceutical Companies

Psoriasis is a chronic autoimmune disorder in which skin cells multiply excessively, creating thick, itchy, scaly patches that affect more than 8 million Americans.

Novartis will direct the funds toward upgrading its manufacturing plant in Beijing and expanding its R&D campus in Shanghai, where it also houses its Chinese headquarters.

The acquisition involves Novartis purchasing Pikavation Therapeutics, a wholly owned subsidiary of Synnovation Therapeutics that holds the rights to SNV4818 and related research programs.

The new production hub will be located in the Lin-gang Special Area of the Shanghai Free Trade Zone, where it will supply autologous CAR-T therapies to China and other Asian markets.

This deal builds on the existing partnership between the two companies and could expand Sandoz’s biosimilar portfolio to an “industry-leading” 32 assets.

The expansion of Cosentyx to this population addresses a critical gap in care and demonstrates Novartis’ focus on advancing solutions where the company can make the greatest impact on patient outcomes.

Alzheimer’s disease drives up to 70% of dementia cases worldwide, presenting healthcare systems with mounting challenges.

Researchers plan to enroll approximately 190 women aged 18 to 45 across seven European countries, including the UK, Italy, Poland, Romania, Bulgaria, the Czech Republic, and Hungary.

The site can produce up to 40 CGMP batches annually, supporting parallel processing for multiple client programs and ensuring reliable supply chains.

The facility will house sophisticated equipment, including liquid-phase peptide synthesis reactors ranging from 250 to 3,000 liters and solid-phase peptide synthesis reactors up to 500 liters.